search
Back to results

Laparoscopic Staging for Locally Advanced Gastric Cancer in Chinese Patients

Primary Purpose

Gastric Cancer, Peritoneal Metastases

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Laparoscopic Staging
Sponsored by
Peking University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Gastric Cancer focused on measuring Gastric Cancer, Laparoscopic Staging, Cytology, Peritoneal Metastases

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • sign written informed consent form
  • age ≥ 18 years
  • pathologically confirmed gastric or GEJ adenocarcinoma
  • disease at clinical stage of locally advanced gastric cancer by CT/EUS(cT2+NanyM0)
  • No prior antitumor treatment is allowed, including chemotherapy, radiotherapy, immune therapy or target therapy
  • Adequate organ function as defined below:

Hematologic ANC ≥ 1.5*109/l Hemoglobin ≥ 9 g/dl Platelets ≥ 100*109/l Hepatic Albumin ≥ 30g/l Serum bilirubin ≤ 1.5×ULN AST and ALT ≤ 2.5×ULN ALP ≤ 2.5×ULN TBIL ≤ 1.5×ULN Renal Serum Creatinine < 1.5 ULN

  • KPS ≥ 70
  • Adequate lung and heart function
  • Negative serum or urine pregnant test within 7 days prior to randomization for child-bearing age women
  • Sexually active males or females willing to practice contraception during the study until 30 days after end of study.

Exclusion Criteria:

  • Refuse to provide blood/tissue sample;
  • With distant metastasis diagnosed by CT/EUS;
  • Sexually active males or females refuse to practice contraception during the study until 30 days after end of study.
  • History of organ transplantation(including autologous bone marrow transplantation and Peripheral stem cell transplantation);
  • Prior long term steroid therapy (excluding short term steroid treatment which is completed prior to > 2 weeks of study enrollment);
  • Patients with central nervous system(CNS) disorder or peripheral nervous system disorder or psychiatric disease;
  • Concurrent severe infection;
  • Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety (including current active hepatic, biliary, renal, respiratory disease, uncontrolled diabetes hypertension et al);
  • History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible;
  • Known history of uncontrolled or symptomatic angina, uncontrolled arrhythmias and hypertension, or congestive heart failure, or cardiac infarction within 6 months prior to study enrollment, or cardiac insufficiency;
  • Person with no capacity (legally) or inappropriate to continue study treatment for ethics/medical reasons.

Sites / Locations

  • Peking Unicersity Cancer HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Laparoscopic Staging

Arm Description

For Patients diagnosed as Locally Advanced Gastric Cancer(cT2+NanyM0)by CT and EUS, undergo laparoscopic staging.

Outcomes

Primary Outcome Measures

Peritoneal Metastasis or Positive Cytology

Secondary Outcome Measures

Safety
Number of Participants with Adverse Events(III or IV grades according to NCI-CTC)

Full Information

First Posted
June 20, 2014
Last Updated
December 6, 2014
Sponsor
Peking University
search

1. Study Identification

Unique Protocol Identification Number
NCT02172690
Brief Title
Laparoscopic Staging for Locally Advanced Gastric Cancer in Chinese Patients
Official Title
Laparoscopic Staging in Patients With Locally Advanced Gastric Cancer in Chinese Patients
Study Type
Interventional

2. Study Status

Record Verification Date
December 2014
Overall Recruitment Status
Unknown status
Study Start Date
June 2014 (undefined)
Primary Completion Date
December 2016 (Anticipated)
Study Completion Date
December 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Peking University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
RATIONALE: Laparoscopic staging may help doctors plan more effective treatment for gastric cancer, yet the efficiency have not been fully investigated in Chinese people. PURPOSE: Study the effectiveness of laparoscopic staging in patients with pre-diagnosed as locally advanced gastric cancer.
Detailed Description
OBJECTIVES: I. Determine the feasibility of laparoscopic staging of patients with pre-diagnosed as locally advanced gastric cancer. II. Assess the adverse effects associated with this technique. OUTLINE: Surgery. Laparoscopy with cytologic examination. PROJECTED ACCRUAL: Up to 450 patients will be accrued over approximately 2 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Cancer, Peritoneal Metastases
Keywords
Gastric Cancer, Laparoscopic Staging, Cytology, Peritoneal Metastases

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
450 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Laparoscopic Staging
Arm Type
Experimental
Arm Description
For Patients diagnosed as Locally Advanced Gastric Cancer(cT2+NanyM0)by CT and EUS, undergo laparoscopic staging.
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic Staging
Intervention Description
Laparoscopic Staging
Primary Outcome Measure Information:
Title
Peritoneal Metastasis or Positive Cytology
Time Frame
7days
Secondary Outcome Measure Information:
Title
Safety
Description
Number of Participants with Adverse Events(III or IV grades according to NCI-CTC)
Time Frame
30days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: sign written informed consent form age ≥ 18 years pathologically confirmed gastric or GEJ adenocarcinoma disease at clinical stage of locally advanced gastric cancer by CT/EUS(cT2+NanyM0) No prior antitumor treatment is allowed, including chemotherapy, radiotherapy, immune therapy or target therapy Adequate organ function as defined below: Hematologic ANC ≥ 1.5*109/l Hemoglobin ≥ 9 g/dl Platelets ≥ 100*109/l Hepatic Albumin ≥ 30g/l Serum bilirubin ≤ 1.5×ULN AST and ALT ≤ 2.5×ULN ALP ≤ 2.5×ULN TBIL ≤ 1.5×ULN Renal Serum Creatinine < 1.5 ULN KPS ≥ 70 Adequate lung and heart function Negative serum or urine pregnant test within 7 days prior to randomization for child-bearing age women Sexually active males or females willing to practice contraception during the study until 30 days after end of study. Exclusion Criteria: Refuse to provide blood/tissue sample; With distant metastasis diagnosed by CT/EUS; Sexually active males or females refuse to practice contraception during the study until 30 days after end of study. History of organ transplantation(including autologous bone marrow transplantation and Peripheral stem cell transplantation); Prior long term steroid therapy (excluding short term steroid treatment which is completed prior to > 2 weeks of study enrollment); Patients with central nervous system(CNS) disorder or peripheral nervous system disorder or psychiatric disease; Concurrent severe infection; Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety (including current active hepatic, biliary, renal, respiratory disease, uncontrolled diabetes hypertension et al); History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible; Known history of uncontrolled or symptomatic angina, uncontrolled arrhythmias and hypertension, or congestive heart failure, or cardiac infarction within 6 months prior to study enrollment, or cardiac insufficiency; Person with no capacity (legally) or inappropriate to continue study treatment for ethics/medical reasons.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jiafu Ji, MD
Phone
0086-10-88196391
Email
jiafuj@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jiafu Ji, MD
Organizational Affiliation
Peking University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Peking Unicersity Cancer Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100142
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jiafu Ji, MD
Phone
86-10-88196391
Email
jiafuj@hotmail.com
First Name & Middle Initial & Last Name & Degree
Jiafu Ji, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
29321007
Citation
Li Z, Li Z, Zhang L, Liu Q, Wang Z, Zhang Z, Xiao G, Fu W, Wang X, Ye Y, Yu J, Li F, Chen L, Wang S, Ji J. Staging laparoscopy for locally advanced gastric cancer in Chinese patients: a multicenter prospective registry study. BMC Cancer. 2018 Jan 10;18(1):63. doi: 10.1186/s12885-017-3791-6.
Results Reference
derived

Learn more about this trial

Laparoscopic Staging for Locally Advanced Gastric Cancer in Chinese Patients

We'll reach out to this number within 24 hrs